Allovectin-7 therapy in metastatic melanoma
- PMID: 18476795
- DOI: 10.1517/14712598.8.6.839
Allovectin-7 therapy in metastatic melanoma
Abstract
Background: Patients with metastatic melanoma are immunosuppressed by the growing tumor. Allovectin-7 therapy is a form of active immunotherapy that aims at immunization of the host with substances designed to elicit an immune reaction that will eliminate or slow down the growth and spread of the cancer.
Objective: to describe the rationale for immunotherapy with Allovectin-7 and assess its safety profile and efficacy based on the results of completed melanoma clinical trials.
Methods: we reviewed both the published medical literature and the results of trials pending publication.
Results/conclusion: Allovectin-7 is a safe and active immunotherapeutic agent. It induces local and systemic durable responses in patients with metastatic melanoma.
Similar articles
-
Velimogene aliplasmid.Expert Opin Biol Ther. 2010 May;10(5):841-51. doi: 10.1517/14712598.2010.481280. Expert Opin Biol Ther. 2010. PMID: 20367461 Review.
-
Immunologic therapy targeting metastatic melanoma: allovectin-7.Immunotherapy. 2011 Jan;3(1):17-21. doi: 10.2217/imt.10.89. Immunotherapy. 2011. PMID: 21174553
-
Efficacy and safety of HLA-B7/beta-2 microglobulin plasmid DNA/lipid complex (Allovectin-7) in patients with metastatic melanoma.Expert Opin Biol Ther. 2003 Apr;3(2):377-84. doi: 10.1517/14712598.3.2.377. Expert Opin Biol Ther. 2003. PMID: 12662150 Review.
-
Technology evaluation: Allovectin-7, Vical.Curr Opin Mol Ther. 2002 Feb;4(1):80-7. Curr Opin Mol Ther. 2002. PMID: 11883699 Review.
-
Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma.J Clin Oncol. 1997 Jan;15(1):341-9. doi: 10.1200/JCO.1997.15.1.341. J Clin Oncol. 1997. PMID: 8996161 Clinical Trial.
Cited by
-
Immunotherapy in the management of melanoma: current status.Immunotargets Ther. 2013 Feb 23;2:1-10. doi: 10.2147/ITT.S30824. eCollection 2013. Immunotargets Ther. 2013. PMID: 27471683 Free PMC article. Review.
-
Clinical evaluation of therapeutic cancer vaccines.Hum Vaccin Immunother. 2013 May;9(5):1049-57. doi: 10.4161/hv.23917. Epub 2013 Mar 1. Hum Vaccin Immunother. 2013. PMID: 23454867 Free PMC article.
-
Immunological monitoring of anticancer vaccines in clinical trials.Oncoimmunology. 2013 Aug 1;2(8):e26012. doi: 10.4161/onci.26012. Epub 2013 Aug 23. Oncoimmunology. 2013. PMID: 24083085 Free PMC article. Review.
-
The role of chemotherapy in the modern management of melanoma.Melanoma Manag. 2014 Nov;1(2):173-184. doi: 10.2217/mmt.14.20. Epub 2014 Dec 4. Melanoma Manag. 2014. PMID: 30190822 Free PMC article. Review.
-
The immune-related role of beta-2-microglobulin in melanoma.Front Oncol. 2022 Aug 16;12:944722. doi: 10.3389/fonc.2022.944722. eCollection 2022. Front Oncol. 2022. PMID: 36046045 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical